Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA in a Ph 1b Clinical Trial in Melanoma April 20, 2023
ESSA Pharma and Janssen to evaluate EPI-7386 in combination with apalutamide and abiraterone acetate plus prednisone in patients with prostate cancer April 20, 2023
CTRL Therapeutics Launches with $10M Seed Financing to Advance Next-Gen Cell Therapy Platform for the Treatment of Solid Tumors April 20, 2023
Enrollment completes in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients April 20, 2023
Initiation of Ph 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma announced April 20, 2023
KEYTRUDA + Chemo Significantly Improved OS Compared to Chemo Alone in Patients With Advanced or Unresectable Biliary Tract Cancer April 20, 2023
mRNA-4157 (V940) + KEYTRUDA combination Demonstrated Superior RFS in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection vs KEYTRUDA April 20, 2023
Imfinzi-based treatment before & after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable NSCLC in the AEGEAN Ph 3 trial April 20, 2023
Positive topline data announced from Part A safety lead-in of THIO-101 Ph 2 trial in advanced NSCLC April 20, 2023
Tecentriq + Avastin reduced the risk of cancer returning in people with adjuvant HCC at high risk of disease recurrence following liver resection in Ph 3 IMbrave050 study April 20, 2023
FDA Accepts Application for KEYTRUDA + Chemo as 1L Treatment for Locally Advanced Unresectable or Metastatic Gastric or GEJ Adenocarcinoma April 20, 2023
